THE interaction between PAF and human platelet membranes was investigated by measuring the steadystate fluorescence anisotropy and fluorescence decay of 1 (4 trimethylammoniumphenyl) 6 phenyl 1,3,5 hexatriene (TMA-DPH) incorporated in platelet plasma membranes. PAF induced a time-limited and significant increase of the lipid order in the exterior part of the membrane and a decrease in membrane heterogeneity. These changes were blocked in the presence of the PAF antagonists, L-659,989 and 1-O-hexadecyl-2-acetyl-snglycero-3-phospho (N,N,N-trimethyl) 
1-s Many cell types are targets for PAF activation. These include human platelets, granulocytes, lymphocytes, endothelial cells and spermatozoa. >5 In platelets, PAF interacts with its specific receptor in the membrane initiating a series of biochemical events associated with the signal 6 transduction process.
This study was performed to discern the effect of PAF on the physico-chemical organization of human platelet membranes. The steady-state fluorescence anisotropy of TMA-DPH incorporated into platelet membranes was measured before and after the addition of PAF in the absence or presence of two PAF antagonists, 1-Ohexadecyl-2-acetyl-sn-glycero- 3- phospho(N,N,Ntrimethyl)hexanolamine.H20 and (__+)-trans-2-(3-methoxy-5 methylsulphonyl-4-propoxyphenyl)-5 (3,4,5-trimethoxyphenyl) tetrahydrofuran (L-659,989). We have also studied the influence of PAF on the fluorescence decay of TMA-DPH which is sensitive to the membrane heterogeneity as previously described. observed after the addition of PAF (10 -7 M). Figure 3 shows the effect of PAF addition to platelets in the presence of 1-O-hexadecyl-2-acetylsn-glycero- 3- phospho(N,N,N 
